Fred Dunaway, MD
Family Medicine · Fort Mitchell, KYNPI 1407812720
Payments from drug & device makers
Across 358 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$777
- AstraZeneca$732
- Pfizer$719
- Amgen$388
- Takeda Pharmaceuticals U.S.A., Inc.$359
- Astellas Pharma US Inc$346
- plus $3K from 31 others
What the payments were for
- Food & beverage$6,11599%
- Education$851%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 40 | $777 |
| AstraZeneca | 26 | $732 |
| Pfizer | 45 | $719 |
| Amgen(2 entities) | 22 | $388 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $359 |
| Astellas Pharma US Inc | 14 | $346 |
| GSK | 24 | $332 |
| Boehringer Ingelheim | 15 | $285 |
| Amarin Pharma, Inc. | 14 | $271 |
| Novo Nordisk | 16 | $263 |
| Lilly USA, LLC | 18 | $254 |
| Merck | 26 | $177 |
| Novartis | 11 | $168 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $160 |
| Exact Sciences | 7 | $152 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $127 |
| Axsome Therapeutics, Inc. | 4 | $114 |
| Bayer | 4 | $66 |
| Xeris Pharmaceuticals, Inc. | 3 | $60 |
| Abbott | 3 | $50 |
| Johnson & Johnson | 3 | $43 |
| Teva Pharmaceuticals USA, Inc. | 3 | $43 |
| Dynavax Technologies Corporation | 4 | $39 |
| Dexcom, Inc. | 1 | $37 |
| Idorsia Pharmaceuticals US Inc | 2 | $25 |
| Hikma Pharmaceuticals USA | 2 | $24 |
| Gilead | 1 | $24 |
| Shield Therapeutics Inc | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Tris Pharma Inc | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $14 |
| Antares Pharma, Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Clarus Therapeutics Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,200 in reported general payments places this provider in the 85th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 177 | $179,695 |
| JardianceEmpagliflozin | 135 | $139,551 |
| FarxigaDapagliflozin Propanediol | 110 | $111,048 |
| JanuviaSitagliptin Phosphate | 80 | $91,130 |
| OzempicSemaglutide | 56 | $86,449 |
| MounjaroTirzepatide | 51 | $58,372 |
| Dupixent PenDupilumab | 12 | $45,876 |
| XareltoRivaroxaban | 49 | $44,377 |
| Repatha SureclickEvolocumab | 46 | $33,195 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 28 | $32,952 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $30,041 |
| TradjentaLinagliptin | 29 | $26,707 |
| TrulicityDulaglutide | 11 | $19,955 |
| EntrestoSacubitril/Valsartan | 14 | $18,236 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $16,375 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $719 | $179,695177 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $285 | $174,882177 claims |
| MerckJanuvia, Janumet Xr | $177 | $124,082108 claims |
| AstraZenecaFarxiga, Symbicort, Bevespi Aerosphere | $732 | $120,050141 claims |
| Novo NordiskOzempic | $263 | $86,44956 claims |
| Lilly USA, LLCMounjaro, Trulicity | $254 | $78,32762 claims |
| Johnson & JohnsonXarelto | $43 | $44,37749 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $332 | $37,20441 claims |
| NovartisEntresto | $168 | $18,23614 claims |
| Astellas Pharma US IncMyrbetriq | $346 | $11,02920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Fort Mitchell
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
- Eleida Tur OlivaLexington$113K
- Jeffrey GreenParis$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.